Appl Health Econ Health Policy. 2013 Sep 28. [Epub ahead of print]
Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment.
Ramírez de Arellano A, Coca A, de la Figuera M, Rubio-Terrés C, Rubio-Rodríguez D, Gracia A, Boldeanu A, Puig-Gilberte J, Salas E.
Source
Departamento Científico, FERRER INCODE, Barcelona, Spain.Abstract
BACKGROUND:
A clinical-genetic function (Cardio inCode®) was generated using genetic variants associated with coronary heart disease (CHD), but not with classical CHD risk factors, to achieve a more precise estimation of the CHD risk of individuals by incorporating genetics into risk equations [Framingham and REGICOR (Registre Gironí del Cor)].OBJECTIVE:
The objective of this study was to conduct an economic analysis of the CHD risk assessment with Cardio inCode®, which incorporates the patient's genetic risk into the functions of REGICOR and Framingham, compared with the standard method (using only the functions).METHODS:
A Markov model was developed with seven states of health (low CHD risk, moderate CHD risk, high CHD risk, CHD event, recurrent CHD, chronic CHD, and death). The reclassification of CHD risk derived from genetic information and transition probabilities between states was obtained from a validation study conducted in cohorts of REGICOR (Spain) and Framingham (USA). It was assumed that patients classified as at moderate risk by the standard method were the best candidates to test the risk reclassification with Cardio inCode®. The utilities and costs (RESULTS:
For a Cardio inCode® price ofCONCLUSIONS:
Cardio inCode® is a cost-effective risk score option in CHD risk assessment compared with the standard method.- PMID:
- 24078223
- [PubMed - as supplied by publisher]
No hay comentarios:
Publicar un comentario